Bringing new pharmaceutical treatments to market is a race against time, especially for the patients who so desperately need them. All too often, overcomplicated operational processes in the early phase of development ends up slowing everything down. It doesn’t have to be that way.
Pharmaceutical companies invest an enormous amount of time, money, and resources into the discovery of new drugs and medical devices. Given the limited window of patent exclusivity, they need to move fast in bringing new products to market if they are to recoup their investment. Not to mention the patients whose quality of life depends on the availability of these treatments. The stakes could not be higher.
A necessary but slow-moving process
Such as logistical complexity, high costs and wasted time/resources
Ensuring compliance, traceability and audit readiness
Regarding energy consumption and materials used
Key solutions include:
Automated GAMP5 validation, tracking and patient safety tools to streamline operations conforming with regulatory guidelines.
Simulations of production costs inform planning, allowing to optimize energy and raw material usage and achieve sustainability targets.
Collaborate with Siemens Digital Industries Software to unlock the power of digital in early pharmaceutical development.